Newswise — BIRMINGHAM, Ala. – The National Institutes of Health awarded the University of Alabama at Birmingham’s Division of Clinical Immunology and Rheumatology a $6.5 million grant to further investigate gout, hyperuricemia and other diseases associated with gout.
“The incidence of gout is increasing worldwide, with around 4 percent of the adult population in the United States affected,” said Kenneth Saag, M.D., M.Sc., director of the UAB INvestigationS In Gout, Hyperuricemia and ComorbidiTies (INSIGHT) Center of Research Translation and Lowe Professor of Medicine. “Gout is a significant burden on the health care system and is associated with both decreased work productivity and quality of life, making it important for us to better understand the disease.”
The goal of the INSIGHT CORT is to conduct innovative translational research projects drawing on the unique strengths of multidisciplinary research teams at UAB, Harvard University, Brigham and Women’s Hospital, University of California San Diego, University of Otago in New Zealand, University of Nebraska Medical Center, and Michigan State University. S. Louis Bridges, M.D., Ph.D., Anna Lois Waters Endowed Chair of the UAB Division of Clinical Immunology and Rheumatology, and Hyon Choi, M.D., DrPH, professor of Medicine at Harvard, will serve as associate directors of the CORT.
Projects within the INSIGHT CORT span the translational basic and pre-clinical spectrum from genetic and molecular underpinnings of hyperuricemia and gout to understanding how urate-lowering therapies for gout might preserve kidney function in gout patients. Collectively, these projects hold promise to increase the clinical understanding of gout and the factors that contribute to debilitating gout flares, providing critical information to the burgeoning field of precision medicine through investigations of novel biomarkers for gout flares and genetic predictors of responsivity to therapies available for gout.
In addition to the four funded projects, the center will foster development of pilot and feasibility projects to encourage the use of new translational methods to research gout, hyperuricemia and associated comorbidities, such as chronic kidney disease and metabolic syndrome. The center will also oversee training activities to promote training of translational investigators in current methods of research applicable to gout and hyperuricemia.
“Our team reflects a focused, relevant, multidisciplinary translational research program dedicated to the development of new knowledge and translational techniques within autoimmune diseases,” Saag said. “We are focused on making significant strides in research findings to better understand this disease that so many people live with on a daily basis.”
Known for its innovative and interdisciplinary approach to education at both the graduate and undergraduate levels, the University of Alabama at Birmingham is the state of Alabama’s largest employer and an internationally renowned research university and academic medical center; its professional schools and specialty patient-care programs are consistently ranked among the nation’s top 50. UAB’s Center for Clinical and Translational Science is advancing innovative discoveries for better health as a two-time recipient of the prestigious Center for Translational Science Award. Find more information at www.uab.edu and www.uabmedicine.org.
EDITOR’S NOTE: The University of Alabama at Birmingham is a separate, independent institution from the University of Alabama, which is located in Tuscaloosa. Please use University of Alabama at Birmingham on first reference and UAB on all subsequent references.
VIDEO: www.youtube.com/uabnews TEXT: www.uab.edu/news TWEETS: www.twitter.com/uabnews